This systematic review and meta-analysis studied toxicant biomarkers in people who switched completely from cigarettes to e-cigarettes. Of sixty included studies, six publications covering seven study-level sources supplied 47 estimates across ten biomarkers. These were pooled as ratios of post-switch to smoking levels using random-effects models. Every pooled biomarker was lower, including the tobacco-specific nitrosamine NNN by 92% and the nitrosamine metabolite NNAL by 61%. Reductions among dual users were smaller and depended on how far cigarettes were displaced. Heterogeneity was substantial (I² 57-99%), and many studies were short-term, product-specific and industry-funded.
Why it is interesting: The pooled figures quantify how far toxicant exposure falls when smokers switch fully to e-cigarettes. Smaller falls among dual users show the reduction depends on cigarettes being displaced completely.
Abstract — the authors' own words, CC BY
Background
Combustible cigarette smoking remains a major preventable cause of premature mortality worldwide, and the public-health relevance of electronic cigarettes depends substantially on whether switching from cigarettes lowers exposure to toxicants associated with smoking-related disease. We systematically reviewed the human biomonitoring evidence and quantified changes in biomarkers of exposure after complete switching from cigarettes to e-cigarettes or exclusive e-cigarette use after cigarette smoking. Methods
PubMed, Scopus and Web of Science Core Collection were searched from inception to 28 May 2026 for human studies reporting biomarkers of exposure or potential harm in relation to e-cigarette use, dual use or switching. Study characteristics, biomarker data and a pragmatic risk-of-bias and funding assessment were extracted in duplicate. Meta-analysis was restricted to biomarkers of exposure with at least two compatible estimates for complete switching or exclusive e-cigarette use after cigarette smoking; dual-use evidence was synthesised narratively. Effects were expressed as ratios of means comparing post-switch with baseline or reference cigarette-smoking levels and pooled using random-effects models with restricted maximum likelihood estimation. Results
Sixty studies were included. Six publications, representing seven study-level sources, contributed 47 biomarker-specific effects across ten biomarkers. Complete switching or exclusive e-cigarette use after cigarette smoking was associated with lower levels of every pooled biomarker. Approximate reductions were 61% for NNAL, 92% for NNN, 72% for 3-HPMA, 84% for the acrylonitrile metabolite CEMA, 77% for HMPMA, 82% for MHBMA, 90% for S-PMA, 79% for exhaled carbon monoxide, 77% for carboxyhaemoglobin and 76% for 1-OHP. Between-study heterogeneity was substantial for most biomarkers (I² 57-99%), and 95% prediction intervals lay entirely below 1.0 only for NNN, CEMA and carboxyhaemoglobin; the pooled values are therefore central estimates rather than precise expectations for any individual future study. Narrative evidence was broadly consistent: exclusive e-cigarette use was generally associated with lower exposure than cigarette smoking, whereas reductions among dual users were smaller and depended on cigarette displacement. Biomarkers of potential harm were more heterogeneous and were not pooled. Many switching studies were short-term, product-specific and industry-funded. Conclusions
Complete switching from cigarettes to e-cigarettes or exclusive e-cigarette use after cigarette smoking is associated with substantially lower biomarkers of exposure to tobacco- and combustion-related toxicants. Exposure reductions appear greatest when cigarette smoking is fully displaced. These findings describe reduced exposure to measured toxicants; they do not, by themselves, establish reduced disease risk or long-term safety.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.
Other drivers in Behavioural science
-
Diet, exercise and sleep
What people eat and how much they move: what the measured evidence says each does to mortality, and what has been shown to change either.
2 this week -
Smoking and vaping
How far smoking has fallen and how many deaths it still causes, what vaping is doing to the people who take it up, and what generational bans will show.
4 this week -
Alcohol and drug use
What is happening to deaths from alcohol, drugs and suicide, whether they move together, and how much of it is behaviour and how much circumstance.
3 this week -
Social connection
Isolation, loneliness and mortality: what the evidence shows, how far the relationship is causal, and what interventions have shown.
None this week Earlier → -
Infection and pandemics
Infection and pandemics: the risks, and how well prepared we are
8 this week -
Adherence and persistence
Whether a treatment is actually taken, for how long, and what changes either.
2 this week
